-
Mashup Score: 6
Original Article from The New England Journal of Medicine — 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer
Source: New England Journal of MedicineCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1
Original Article from The New England Journal of Medicine — 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer
Source: New England Journal of MedicineCategories: Latest Headlines, Oncologists1Tweet-
Few days before its update at #SABCS21, published in @NEJM results of #RxPONDER trial on role of #OncotypeDx in informing about #chemotherapy benefit in node+ early #BreastCancer: negative trial overall but useful in postmenopausal pts @OncoAlert #bcsm https://t.co/nNnBR9u6Sb
-
-
Mashup Score: 3Practice-Changing Use of the 21-Gene Test for the Management of Patients With Early-Stage Breast Cancer in Latin America - 3 year(s) ago
PURPOSE We present a physician survey of the impact of 21-gene Breast Recurrence Score test results on treatment decisions in clinical practice in Latin America. METHODS This prospective survey enrolled consecutive patients at 14 sites in Argentina, Colombia, Mexico, and Peru who had routine 21-gene testing. Physician surveys captured patient and tumor characteristics and treatment decisions…
Source: JCO Global OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Doctors in Latin America use #OncotypeDX test results to de-escalate treatment for low genomic risk #BreastCancer https://t.co/bYUSIJ0utc @OncotypeIQ #bcsm #JCOGO https://t.co/1M16dXKeqZ
-
-
Mashup Score: 3The Role of Oncotype DX® Recurrence Score in Predicting Axillary Response After Neoadjuvant Chemotherapy in Breast Cancer - 3 year(s) ago
Introduction Oncotype DX® recurrence score (RS) is well-recognized for guiding decision making in adjuvant chemotherapy; however, the predictive capability of this genomic assay in determining axillary response to neoadjuvant chemotherapy (NCT) has not been established. Methods Using the National Cancer Data Base (NCDB), we identified patients diagnosed with T1-T2, clinically N1/N2, estrogen…
Source: Annals of Surgical OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
MARCH ISSUE: The Role of #OncotypeDX® Recurrence Score in Predicting Axillary Response After #NeoadjuvantChemotherapy in #BreastCancer. https://t.co/28r4I9eXUU @McMastersKelly @SocSurgOnc https://t.co/kk3sOsFl8r
-
-
Mashup Score: 4Molecular Drivers of Oncotype DX, Prosigna, EndoPredict, and the Breast Cancer Index: A TransATAC Study - 4 year(s) ago
PURPOSE The Oncotype DX Recurrence Score (RS), Prosigna Prediction Analysis of Microarray 50 (PAM50) Risk of Recurrence (ROR), EndoPredict (EP), and Breast Cancer Index (BCI) are used clinically for estimating risk of distant recurrence for patients receiving endocrine therapy. Discordances in estimates occur between them. We aimed to identify the molecular features that drive the tests and lead…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Interesting results in @ASCO_pubs from the #TransATAC study suggesting a possible explanation for the differences in the prognostic performance of genomic tests in #BreastCancer #OncotypeDX #Prosigna #EndoPredict #BreastCancerIndex @OncoAlert @ASCO #bcsm https://t.co/TpmCg5x8KH
-
Good evidence that many post-menopausal women with the most common form of breast cancer (hormone receptor+, HER2 neg) and 1-3 positive lymph nodes can avoid chemo, @NEJM - https://t.co/JFvV2hIs7M #OncotypeDx @ExactSciences #bcsm #LessIsMore https://t.co/8L5MCKzFZo